Buy Rating Affirmed for Arrowhead Pharmaceuticals Amid Promising Plozasiran Developments
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Truist Secu
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $60
H.C. Wainwright analyst Patrick Trucchio maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and adjusts the target price from $90 to $60.According to TipRanks data, the analyst has a su
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | Arrowhead Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $60 From $90
Express News | HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Lowers Price Target to $60
Form 144 | Arrowhead Pharmaceuticals(ARWR.US) Officer Proposes to Sell 237.41K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 2, $Arrowhead Pharmaceuticals(ARWR.US)$ Officer Oliver Tracie intends to sell 9,394 shares of its common stock on Jul 2, with a total market value of approximately $237.41K
The Past Three Years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Investors Has Not Been Profitable
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
TD Cowen analyst Brendan Smith maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.5% and a total average return of -3.2%
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29
Citi analyst David Lebovitz maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a hold rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 51.4%
Express News | Arrowhead Pharmaceuticals Inc - Will Assess Partnership Options for Future Development of Zodasiran
Express News | Arrowhead Pharmaceuticals to Advance Rnai-Based Plozasiran Into Phase 3 Capitan Cardiovascular Outcomes Trial
Does This Valuation Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Imply Investors Are Overpaying?
Key Insights The projected fair value for Arrowhead Pharmaceuticals is US$21.65 based on 2 Stage Free Cash Flow to Equity Arrowhead Pharmaceuticals' US$27.24 share price signals that it might be 26%
Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were trading higher by 6% to $27.54 during Monday's session after the company announced that it presented preclinical data on ARO-INHBE at the Americ
Sector Update: Health Care Stocks Advance Monday Afternoon
Health care stocks rose in Monday afternoon trading, with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) climbed
Express News | Arrowhead Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Presented Preclinical Data on ARO-INHBE at the American Diabetes Association 84th Scientific Sessions
Express News | Arrowhead Pharmaceuticals Shares up 3.5% Premarket After Positive Preclinical Data for Obesity Treatment
Arrowhead Pharmaceuticals Unveils Obesity Treatment at ADA Conference
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.